Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children
Status:
Completed
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety and
antiviral effect of current standard antiretroviral therapy compared to once daily integrase
inhibitor administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically
suppressed paediatric participants.